Serotonin (5-hydroxytryptamine; 5-HT) is generally associated with its actions in the central nervous system (CNS) as a neurotransmitter involved in activities such as mood regulation, food consumption, sleep, sex and pain
1
. However, CNS serotonin only accounts for a small proportion of the body's total 5-HT, as the vast majority of 5-HT is located in the gut 2, 3 . Within the wall of the gut, 5-HT acts as a paracrine signalling molecule and as a neurotransmitter to initiate and modify the major regulatory functions of the gut, namely motility, secretion and vasodilation. These conventional actions of 5-HT have been the topic of many investigations and review articles 4 , and it should be noted that the roles of 5-HT in intestinal motility are still rather controversial, as debated in two articles published in 2015 (REFS 5, 6) . This Review focuses on some of the newly discovered non-neuronal, and less conventional, roles of peripheral serotonin both within the gut wall and in other peripheral tissues, which we will herein refer to as non-conventional signalling.
Sources of peripheral serotonin
The first investigations of the signalling molecule that we now know as serotonin were carried out on peripheral tissue and blood samples. In 1937, Vittorio Erspamer isolated an indolalkylamine that he called "enteramine" from the gastrointestinal tracts of a variety of vertebrates, and he, ultimately, concluded that it is the major secretory product of the enterochromaffin (EC) cells of the gastrointestinal mucosa 2, 3 . In 1948, Page et al. 7 isolated a compound from bovine serum that they called serotonin owing to its action as a vasoconstrictor. Rapport and colleagues identified the structure of serotonin as , and Erspamer subsequently demonstrated that enteramine is also 5-HT 3 . Studies of the levels of 5-HT and its metabolite, 5-hydroxyindole acetic acid (5-HIAA), in blood, urine and tissues from rats undergoing total gastro enterectomy led to the conclusion that the gastro intestinal mucosa is the major source of peripheral 5-HT 9 . In 1960, 3 days follow ing removal of the stomach and intestines, Bertaccini et al. 9 reported "a virtual disappearance of 5-HIAA from the urine and a considerable lowering of 5-HT in blood, spleen and lungs", without a change in 5-HIAA levels in the brain. These findings indicated that central and peripheral 5-HT stores represent separate entities, and that the principal source of 5-HT in the periphery is the gut.
Neurotransmitter
Compounds that are released from neurons that can affect the physiology of nearby cells.
Non-conventional features of peripheral serotonin signalling -the gut and beyond
Stephanie N. Spohn 1, 2 and Gary M. Mawe 1 Abstract | Serotonin was first discovered in the gut, and its conventional actions as an intercellular signalling molecule in the intrinsic and extrinsic enteric reflexes are well recognized, as are a number of serotonin signalling pharmacotherapeutic targets for treatment of nausea, diarrhoea or constipation. The latest discoveries have greatly broadened our understanding of non-conventional actions of peripheral serotonin within the gastrointestinal tract and in a number of other tissues. For example, it is now clear that bacteria within the lumen of the bowel influence serotonin synthesis and release by enterochromaffin cells. Also, serotonin can act both as a pro-inflammatory and anti-inflammatory signalling molecule in the intestinal mucosa via activation of serotonin receptors (5-HT 7 or 5-HT 4 receptors, respectively). For decades, serotonin receptors have been known to exist in a variety of tissues other than the gut, but studies have now provided strong evidence for physiological roles of serotonin in several important processes, including haematopoiesis, metabolic homeostasis and bone metabolism. Furthermore, evidence for serotonin synthesis in peripheral tissues outside of the gut is emerging. In this Review, we expand the discussion beyond gastrointestinal functions to highlight the roles of peripheral serotonin in colitis, haematopoiesis, energy and bone metabolism, and how serotonin is influenced by the gut microbiota.
Enterochromaffin cell
A subset of enteroendocrine cells in the gastrointestinal epithelium that produce, store and release serotonin.
Enteric neuron
Neurons located in the myenteric or submucosal plexuses that are part of the enteric nervous system.
β cells
Pancreatic β cells are endocrine cells in the pancreas that produce insulin.
Enteric nervous system
Third division of the autonomic nervous system, along with the sympathetic and parasympathetic divisions; consists of the ganglia and nerves within the wall of the gut, and it is unique in that it contains intrinsic reflex circuitry that can locally regulate motility, secretion and blood flow.
Short-chain fatty acid
Fatty acid with a backbone consisting of 2-6 carbon atoms; also known as volatile fatty acid.
Myenteric plexus
A ganglionated plexus of the enteric nervous system that is situated between the circular and longitudinal muscle layers; neural circuits in this plexus provide output to the muscle layers and are responsible for generating motility patterns in the gastrointestinal tract.
The concept that central and peripheral 5-HT are distinct pools is supported by the knowledge that the blood-brain barrier is fairly impermeable to 5-HT, and that different forms of the rate-limiting synthetic enzyme, tryptophan hydroxylase (TPH), are used by neuronal and non-neuronal cells, with TPH2 used by neurons (including enteric neurons) and TPH1 used by EC cells 10, 11 . The realization that non-neuronal cells use TPH1 has been instrumental to the expansion of our appreciation of the physiological roles of 5-HT in many peripheral tissues, and the determination that, although the gut contains by far the highest concentration of 5-HT, there are additional sites of peripheral 5-HT synthesis by TPH1 whereby local release could have a major physiological effect. These sites include pancreatic β cells 12, 13 , adipocytes 14 and osteo clasts 15 . As described later, the finding that gut mucosal 5-HT levels can be influenced by luminal factors, including microorganisms, and how it can influence the inflammatory state and integrity of the epithelial layer are emerging topics of interest. Furthermore, findings from Tph1-knockout mice have led to a new appreci ation of the roles of 5-HT in haemato poiesis, insulin secretion, hepatic glucose handling, adipocyte function and bone metabolism.
Serotonin and the gut microbiota Dietary nutrients and microbial by-products are generally accepted to influence gut function, both directly through actions on the enteric nervous system (ENS) and indirectly via receptor stimulation on enteroendocrine cells 16 . Microorganisms have now been shown to influence the amount of 5-HT that is synthesized by EC cells, as well as 5-HT release.
Reigstad et al. 17 have demonstrated that luminally applied short-chain fatty acids (SCFAs) such as acetate and butyrate, which are produced by human gut microorganisms that ferment dietary saccharides 18 , increase Tph1 mRNA expression and 5-HT synthesis by EC cells (FIG. 1) . When germ-free mice are colonized with human gut microbiota and key elements of 5-HT signalling are evaluated, TPH1 expression and mucosal 5-HT levels are increased, with no change in EC cell number or expression of the serotonin transporter (SERT, also known as sodium-dependent serotonin transporter), suggesting that the gut microbiota influence EC cell function through SCFAs 18 . Functionally, in isolated guinea pig colon, it has been shown that luminal treatment with SCFAs can alter gut motility such that butyrate increases full propagating contractions in the proximal colon and propionate inhibits full propagating waves 19 . In addition to 5-HT release in response to surface receptor stimulation (such as via 5-HT 4 receptors 20 ), 5-HT release from EC cells can also be activated by mechanical stimulation, and evidence indicates that these cells express PIEZO2 mechanosensitive ion channels that have an important role in this process 21 . Together, these findings suggest that gut bacteria that produce SCFAs might be an alternative approach to altering 5-HT availability and, in turn, motility and secretion in the gut.
The concept that gut bacteria can influence colonic motility by regulating mucosal 5-HT is further supported by research by Yano et al. 22 , who demonstrated that indigenous gut bacteria upregulate the TPH1 activity of EC cells to increase 5-HT levels both in the colon and in the blood, resulting in increased myenteric plexus stimulation and, therefore, gut motility in mice. Importantly, they reported that the modulation of 5-HT through gut microbiota manipulation in germ-free and specific pathogen-free mice treated with antibiotics was inducible and reversible, showing that modulation can occur at any point and might be a therapeutic approach.
Although it is possible that 5-HT released from EC cells and entering the lumen could influence the gut microbiota, to our knowledge, no data currently support this hypothesis. For example, 5-HT receptors have not yet been identified on enteric bacteria.
Pro-inflammatory and anti-inflammatory actions
Mucosal 5-HT is a pro-inflammatory signalling molecule. Inflammation is a complex biological immune response by the body's tissue to damage from pathogens or irritants, with the goal of removing the provoking stimulus. The immune response is the coordinated effort of many cell types, pathways and signalling molecules in the organism. In IBD, inflammation is thought to result from an abnormal or unregulated mucosal immune response to either the gut microbiota or a self-antigen 23 . Mounting evidence indicates that, within the intestinal mucosal layer, serotonin can act as both a pro-inflammatory and an anti-inflammatory signalling molecule (FIG. 2) .
Strong support now exists for the concept that 5-HT released from EC cells acts as a pro-inflammatory molecule. The Gershon and Khan research teams took two different approaches to reach the same conclusion. Gershon and colleagues reported that experimental colitis is augmented in mice lacking SERT, which presumably increases serotonin availability when it is released from EC cells 24 . Khan and colleagues simultaneously demonstrated that mice were protected from colitis when mucosal serotonin synthesis was diminished by the TPH inhibitor, parachlorophenylalanine, and in Tph1-knockout mice 25 . Subsequent studies have shown that treatment of mice with a TPH1 inhibitor has a protective effect in models of colitis 26, 27 . The Khan team has gone on to identify dendritic cells as a key player in
Key points
• Serotonin is an important molecule that was first discovered in the gut and contributes to the activation of intrinsic and extrinsic gastrointestinal reflexes • Enterochromaffin cells are the major source of serotonin in the gut and in platelets, but we now know that serotonin is also synthesized in other peripheral tissues • Serotonin synthesis and release by enterochromaffin cells is influenced by gut microorganisms via the generation of short-chain fatty acids • In the intestinal mucosa, serotonin can act to promote inflammation, but also to protect from and reverse inflammation through activation of dendritic cell 5-HT 7 receptors and epithelial 5-HT 4 receptors, respectively • Serotonin influences metabolic homeostasis through actions in pancreatic islets, in the liver and in adipose tissue • Within bone, serotonin acts both in the bone marrow to stimulate haematopoiesis and also in osseous tissue to influence bone metabolism
Glial cell
Non-neuronal cells in neural tissues that provide structural and functional support that aids in proper neurotransmission.
the serotonin-mediated pro-inflammatory response 28 . The 5-HT 7 receptor is expressed on dendritic cells, and following pharmacological inhibition of this receptor, experimentally induced colitis is alleviated, supporting the role of mucosal serotonin acting on key immune cells to produce gut inflammation 29 . Gershon has proposed that serotonin acts as a 'sword and a shield' in the gut and, in this model, the pro-inflammatory actions of sero tonin serve as the 'sword' by mobilizing an immune response to protect the gut from invasion 30 . Not only can serotonin induce changes in immune cells and cause inflammation, but immune cells can also influence EC cell biology and alter serotonin handling in the mucosa. Activated immune cells can secrete type 1 and type 2 T-helper-cell-predominant cytokines that can activate EC cell formation, synthesis and secretion 31 , and SERT levels are decreased in inflammation 4 , probably owing to the actions of TNF and IFNγ 32 . Thus, increased serotonin availability in the inflamed gut could be implicated as a feed-forward pro-inflammatory factor in gastrointestinal pathophysiology.
Mucosal 5-HT is an anti-inflammatory signalling molecule in the gut. In addition to the pro-inflammatory action already described, new evidence suggests that serotonin can also exert an anti-inflammatory effect in the intestinal mucosa via activation of epithelial 5-HT 4 receptors 33 . In dextran sulfate sodium (DSS) and trinitro benzene sulphonic acid (TNBS) colitis, activation of epithelial 5-HT 4 receptors has an anti-inflammatory effect in both protection and recovery paradigms. A number of mechanisms seem to contribute to the protective effect of 5-HT 4 receptor activation, including enhanced epithelial proliferation, accelerated wound healing, and increased resistance to oxidative-stress-induced apoptosis 33 . In addition, the 5-HT 4 receptor also seems to be physiologically important for the integrity of the epithelial layer as in wild-type mice, daily administration of a 5-HT 4 antagonist leads to an increase in disease activity index and histological damage scores, decreased epithelial proliferation, increased bacterial translocation to the liver and spleen, and disrupted motility 33 . Furthermore, 5-HT 4 -knockout mice have a higher histological damage score than wildtype littermates. These results suggest that a luminally restricted 5-HT 4 agonist might be effective in treating IBD.
The question remains, how does one reconcile these contradictory pro-inflammatory and anti-inflammatory actions of 5-HT in the colonic mucosa? One possibility is that the anti-inflammatory, protective 5-HT 4 -receptormediated action predominates under basal conditions, and the pro-inflammatory 5-HT 7 -mediated action predominates in pathological conditions. This hypothesis is supported by the findings that deletion or inhibition of the 5-HT 4 receptor results in an onset of inflammatory scores in the tissue, whereas SERT-knockout mice do not have inflamed intestinal tissue under basal conditions. It is also possible that the pro-inflammatory actions are manifested in pathological conditions when inflammation is already developing, and 5-HT availability is increased owing to decreased SERT expression. This hypothesis is consistent with the 'sword' component of Gershon's sword and shield theory.
Enteric protection and survival
Consistent with the defensive, anti-inflammatory actions of 5-HT in the mucosa, 5-HT acting via 5-HT 4 receptors seems to have a protective role and contributes to enteric neuronal development and survival. In mice lacking enteric neuronal 5-HT due to a loss of TPH2 in the gastrointestinal tract, there is a reduction in the normal development of late-born enteric neurons, particularly those that express dopamine and γ-aminobutyric acid (GABA) 34 . Additionally, there is evidence that 5-HT signal ling through the 5-HT 4 receptor mediates postnatal enteric growth, survival and maintenance, as 5-HT 4 -knockout mice exhibit a loss of enteric neurons after the first few months of life 35 . Consistent with this finding, mice with an overactive form of SERT have altered motility that is associated with fewer enteric neurons, and these deficits are reversed by 5-HT 4 receptor agonist treatment 36 . Agonists of the 5-HT 4 receptor also protect enteric neurons from oxidative stress-induced injury and cell death 37 . In a DSS mouse model of injury, colitis and its associated increase in 5-HT promoted enteric neuro genesis, and this effect was attributed to the 5-HT 4 receptor as it was blocked by a 5-HT 4 antagonist 38 . This group also described a serotonin-5-HT 4 receptormediated trans differentiation of enteric glial cells into neurons, as there was an increase in glial cell number but no marked increase in final glial cell counts, as well as an increase in enteric neurons without the associated increase in neuronal cell proliferation 38 . Moreover, locally applied 5-HT 4 receptor agonists promote enteric nerve circuitry repair in the distal colon of guinea pigs that underwent transection and anastomosis 39 . In addition to facilitating enteric neuron survival and connectivity, 5-HT, possibly from EC cells and/or descending interneurons, promotes interstitial cell of Cajal proliferation and network density via stimulation of the 5-HT 2B receptor 40 . Collectively, strong support exists for a role of 5-HT in the development and function of enteric circuits, as well as a protective or helpful role in enteric recovery.
5-HT and haematopoiesis
The concept that 5-HT could play a part in haematopoiesis was initially proposed decades ago, but the mechanisms involved and the importance of 5-HT signalling in blood cell production and survival is now becoming clear. In 1970, Lowy and colleagues demonstrated that treatment of mice with subcutaneous administration of 5-HT led to an increase in haematocrit that was blocked by nephrectomy or immunoneutralization of erythropoietin 41 . They also showed that the 5-HT treatment decreased blood flow to the kidneys, spleen and liver, but did not affect femoral blood flow. These findings suggested that 5-HT can enhance erythropoiesis at least in part by decreasing oxygen tension in the kidneys and, therefore, promoting erythropoietin formation, but it was not clear whether this action of 5-HT was physiologically relevant or if it was simply a pharmacological phenomenon.
The focus of 5-HT's effects on haematopoiesis has now turned to the bone marrow and haematopoietic stem or progenitor cells (FIG. 3) . Treatment with 5-HT elicits an expansion of cultured umbilical cord blood CD34 + cells to early stem or progenitors and multi-lineage progenitors, and it can stimulate bone marrow stromal cell formation 42 . Furthermore, 5-HT, acting on 5-HT 2 receptors, promotes mitogenesis in megakaryocytes 43 , and it also exerts an anti-apoptotic effect on the megakaryocyte lineage 42 . On the basis of their findings, Yang and colleagues concluded that 5-HT is involved in promoting haematopoietic stem cells and the bone marrow microenvironment, and that 5-HT could be used for ex vivo expansion of haematopoietic stem cells for transplantation.
In studies involving Tph1-knockout mice, compelling evidence has been provided that 5-HT has an important physiological role in erythropoiesis and RBC survival 44, 45 . Mice lacking the Tph1 gene have macrocytic anaemia due to a decreased bone marrow red blood cell (RBC) production 45 . The deficit involves both a hampered progression of precursors towards terminal differentiation, and a shortened survival of mature RBCs. Ex vivo studies have demonstrated that these erythroid precursors from Tph1-knockout mice exhibit decreased prolifer ative capacity that is reversed upon exposure to 5-HT 45 . Furthermore, erythrocytes from TPH1-null mice are more sensitive to phagocytosis by macrophages and have a shortened in vivo half-life. In both in vivo and ex vivo conditions, the presence of 5-HT protects RBCs from senescence 44 . Interestingly, the RBC-maintenance effect of 5-HT involves an antioxidant mechanism that does not entail classic ligand-receptor coupling as no known 5-HT receptors can be detected on these cells. These data support the potential usefulness of ex vivo exposure of blood samples to 5-HT to improve RBC survival during blood banking. Treating stored RBCs with 5-HT in a mouse model of blood banking extends the viable window for use and enhances RBC survival post-transfusion up to nearly four times as long as measured by carboxylfluorescein diacetate succinimidyl ester positive cells 44 . Collectively, these investigations indicate that 5-HT is a key regulator of RBC generation and maintenance, but it remains to be determined whether the 5-HT physiologically arises from a local source in the bone marrow and/or it originates from gut-derived 5-HT circulating in platelets.
5-HT and metabolic homeostasis
Another hot topic in the field of peripheral 5-HT is the rapidly increasing appreciation of its roles in obesity and energy metabolism. Initially, a report showed that tryptophan, the precursor of 5-HT, was reduced in people with obesity and that even weight loss did not improve the circulating tryptophan concentrations 46 . Later it was shown that liver and serum metabolites, including 5-HT, were increased in obese mice 47 . Rats fed a Western diet (a diet high in refined sugars and saturated fats, and low in plant fibre) exhibit increased body weight, blood glucose levels, peak 5-HT release from intestinal EC cells, and increased steady state 5-HT levels with a decrease in SERT function 48 . These findings are interesting because, although it is known that 5-HT is involved in appetite regulation in the CNS 49 , peripheral 5-HT should not influence CNS targets. Thus, it is important to examine how circulating 5-HT might be modulating energy metabolism and obesity.
Pancreatic β cells. Increasingly, it is becoming clear that 5-HT is actively involved in glucose metabolism in the pancreas and liver. In the pancreas, 5-HT contributes to insulin production, secretion and β-cell mass 11, 12 . Pancreatic islet β cells are capable of synthesizing 5-HT, as they express both TPH1 and TPH2, and 5-HT is co-stored along with insulin in β-cell secretory granules 12, 13 . Acting in a receptor-independent manner, through a process called serotonylation, intracellular 5-HT can promote glucose-mediated insulin secretion 13 . The importance of β-cell-generated 5-HT is underscored by the finding that β-cell-specific deletion of TPH1 leads to attenuated insulin secretion, suppressed circulating insulin levels and impaired glucose tolerance in a mouse model of diet-induced insulin resistance 50 . In addition to influencing β-cell function through serotonylation, 5-HT can act via receptor-dependent mechanisms to influence insulin secretion and β-cell mass. Diet-induced insulin-resistant mice devoid of 5-HT 3 receptors exhibit impaired insulin secretion and glucose intolerance 50 . In conditions of elevated demand for insulin (such as pregnancy), pancreatic β-cell mass and insulin secretion increase. In pregnant mice, lactogenic hormones as well as TPH1 and TPH2 expression levels are increased, and 5-HT acts via 5-HT 2B receptors to increase β-cell mass and to increase β-cell responsiveness to glucose. Consistent with this finding, mice lacking the 5-HT 2B receptor develop gestational diabetes 12 . Taken together, these findings indicate that 5-HT produced locally by pancreatic β cells acts through receptor-dependent and indepen dent mechanisms to modulate β-cell numbers, glucose sensitivity and insulin secretion. Additionally, different mech anisms exist for acute and chronic changes in glucose in primary EC cells, such that acute changes result in available calcium ion and 5-HT secretion, whereas chronic changes result in transcriptional regulation of TPH1 activity, which is probably because of changes in availability of nutrients during fasting 51 .
Hepatocytes. Serotonin also influences glucose handling in the liver, but in this case, it is gut-derived 5-HT that is mediating the effects. In the liver, 5-HT arising from intestinal EC cells stimulates gluconeogenesis and decreases uptake of glucose by hepatocytes 52 . This action of 5-HT seems to involve the 5-HT 2B receptor, as suppression of this receptor in hepatocytes increases glucose uptake and decreases glucose production -the same changes that are detected in mice in which Tph1 gene expression has been selectively suppressed in intestinal epithelium. In pancreatic β cells, 5-HT contributes to insulin production and can promote glucose-mediated insulin secretion. In white adipocytes, 5-HT suppresses lipogenesis (increasing lipolysis) and impairs the insulin responsiveness. In bone, there is evidence for a role for 5-HT signalling in bone metabolism and remodelling via osteoblasts. Finally, bacteria in the gut can readily influence 5-HT synthesis via microbial by-products such as short-chain fatty acids (SCFAs). SSRI, serotonin-selective reuptake inhibitor; TPH1, tryptophan 5-hydroxylase 2.
Adipose tissue
Tissue that consists primarily of adipocytes, which are cells that store fat for energy and insulation.
Leptin
A hormone produced in adipose tissue that regulates fat storage in the body as well as appetite.
Adipose tissue. Another mechanism by which 5-HT influences metabolic homeostasis is through actions in adipose tissue, whereby 5-HT originating from both the gut and locally from adipocytes is involved. The action of 5-HT on white adipocytes is similar to that described for hepatocytes in that gut-derived 5-HT can act on 5-HT 2B receptors to stimulate lipolysis via activation of hormone-sensitive lipase 52 . Serotonin stimulation in these cells also seems to suppress lipogenesis and to impair responsiveness to insulin 53 . Another group showed that in mice on a high-fat diet, inhibiting 5-HT synthesis in adipocytes, either pharmacologically or by an inducible Tph1-knockout, reduced weight gain, improved glucose tolerance and decreased lipogenesis in white adipose tissue 53 . Furthermore, in a diet-induced model of type 2 diabetes mellitus, inhibiting TPH1, and therefore gut-derived 5-HT, improved glucose tolerance 52 . Possibly, 5-HT acts on adipocytes via an autocrine mechanism, as these cells seem to express TPH1 and SERT in addition to 5-HT 2 receptors 14 .
Serotonin also influences the functions of brown and beige adipocytes, which are involved in thermo regulation. Serotonin levels are elevated in brown adipose tissue of obese mice, which leads to decreased thermogenesis and energy dissipation by brown adipocytes, prob ably by suppressing β-adrenergic-induced expression of mitochondrial uncoupling protein 1 (REF. 54 ).
Serotonin and bone remodelling
Throughout life, our bones undergo a constant process of remodelling that entails the coordinated activities of osteoblasts, which lay down bone, and osteoclasts, which absorb bone 55 . The formation of osteoblasts and osteoclasts, as well as their levels of activity, are regulated by a variety of signalling molecules that include growth factors, hormones and cytokines 55 . In the past few years, 5-HT has joined the long list of molecules that can influence bone metabolism, and in the case of 5-HT, the story is somewhat complicated because 5-HT can exert divergent effects on bone density depending on the site of 5-HT synthesis and the site(s) of action.
Brain-derived serotonin. Serotonin synthesized by brainstem raphe neurons acts within the CNS to promote bone growth by activating 5-HT 2C receptors on neurons in the ventromedial hypothalamic nuclei, which increases sympathetic tone 56 . Within the bone, increased sympathetic tone acts to promote osteoblast proliferation while also inhibiting proliferation and differentiation of osteoclasts in mice. This process seems to be modulated, in part, by leptin 56 . Leptin, released from adipocytes, decreases 5-HT synthesis and excitability of serotonergic neurons in the raphe nuclei, thereby inhibiting the central serotonergic positive influence on bone mass accrual 56 .
Gut-derived serotonin. Our appreciation of the possibility that gut-derived 5-HT could be an important regulator of bone metabolism began as a result of efforts to understand the mechanism by which a member of the low-density lipoprotein receptor family, LRP5, influences bone formation. Mutations that affect human LRP5 gene expression lead to high bone mass syndrome or osteoporosis when gene function is increased or decreased, respectively 57, 58 . Transcriptome analysis of Lrp5-knockout mice led Yadav and Karsenty to intestinal EC cells because TPH1 expression was drama tically increased in the absence of the Lrp5 gene, which, in turn, led to increased circulating 5-HT levels and decreased bone density 59 . They showed that 5-HT synthesized by EC cells decreased osteoblast proliferation via activation of 5-HT 1B receptors located on pre-osteoblasts 59 . Kousteni and colleagues provided further support for a gut−5-HT-bone axis by demonstrating that the transcription factor, FOXO1, is a critical determinant of the effects of gut-derived 5-HT on osteoblast proliferation in mice 60 . The finding that gut-derived 5-HT can suppress bone growth by decreasing the osteoblast-to-osteoclast ratio has led to the proposal that osteoporosis might be alleviated by regulating enteric 5-HT synthesis with inhibitors of TPH1. Indeed, in mouse and rat models of osteoporosis involving ovariectomy, pharmacological inhibition of TPH1 improved bone formation 61 .
Others have generated data in support of the concept that gut-derived, circulating 5-HT does have a negative effect on bone formation. When circulating concentrations of 5-HT were decreased or increased, increases and decreases in bone volume were observed, respectively, in rats 62, 63 . Notably, Cui et al. 64 have failed to detect altered bone formation when the Lrp5 gene is selectively inactivated in the intestine in mice, but they have found that bone-specific modulation of Lrp5 expression does alter bone cell function (osteocytes) and bone metabolism, so this story is still emerging. Furthermore, this group reported that bone growth therapeutics with TPH1 inhibitors were ineffective compared with the current anabolic treatment, teriparatide, in mice 64 .
Bone-derived 5-HT. As though the divergent influences of 5-HT on bone formation, when comparing CNSderived versus gut-derived 5-HT, were not perplexing enough, it has also been demonstrated that peripheral 5-HT can also promote bone formation, and in this case, the 5-HT is originating from the bone itself. Osteoclasts can express TPH1 and produce 5-HT under certain conditions, such as in the presence of receptor activ ator of nuclear factor kappa-B ligand (RANKL), and in a related finding, Tph1-null mice exhibit both an increase in osteoblast activity and a decrease in osteoclastogenesis compared with wild-type mice 15 .
SERT and bone metabolism. Further evidence that 5-HT acts as a signalling molecule important for bone metabolism is provided by clinical and experimental modulation of SERT function and expression. It has come to light that patients taking serotonin-selective reuptake inhibitors (SSRIs) have decreased bone mass and increased risk of fractures 65 . Many studies have linked depression and treatment for depression to osteoporosis, and have shown that more severe levels of depression are correlated to decreased bone mineral density 65 . Several factors could contribute to bone loss in depression: behavioural factors such as cigarette or alcohol use; biological factors such as increased cortisol and inflammation; confounding factors such as Crohn's disease or diabetes mellitus; and anti-depressant medication use such as SSRIs 66 . Any or all of these factors can influence 5-HT signalling components and, therefore, alter bone metabolism. Mouse models lacking SERT or those treated with SSRIs, effectively reducing SERT activity, also have reduced bone growth 67 . As previously mentioned, osteoblasts express 5-HT 1B receptors as well as SERT 68 . One example of potential biological factors is that patients with a high expressing SERT genotype, or a low expressing 5-HT 1B genotype, had reduced bone formation over 12 weeks of SSRI treatment 68 .
Conclusions
This Review has highlighted a number of nonconventional physiological actions of 5-HT in peripheral systems, including the gut, that go beyond the well-known actions related to gastrointestinal motility and secretion. Within gastrointestinal mucosa, synthesis and release of 5-HT can be influenced by micro organisms, and in addition to stimulation of intrinsic and extrinsic reflexes, this 5-HT can promote or suppress inflammation via 5-HT 7 and 5-HT 4 receptors, respectively. The presence of anti-inflammatory targets in the intestinal lining makes the development and testing of luminally restricted 5-HT 4 agonists an interesting opportunity for a potentially safe and effective treatment of IBD.
Outside the gut, 5-HT seems to have a variety of physiological actions, including those related to haemato poiesis and red blood cell survival, metabolic homeostasis and bone metabolism. Other possible actions (BOX 1) not covered here include mammary gland development 69 , allergic airway inflammation 70 and intercellular signalling in taste buds 71 . The appreci ation of these contributions of 5-HT to an assortment of body functions offers opportunities to gain a better understanding of the mechanisms involved in their regulation, as well as drawing attention to systems that could be inadvertently affected by therapies that target elements of 5-HT signalling. For example, treatment with SERT inhibitors, which increase 5-HT availability wherever it is being released, can lead to altered gut function and sensation as well as osteoporotic conditions.
Although it was long-presumed that all peripheral 5-HT was derived from the gastrointestinal tract and circulating in platelets, it is becoming clear that there are a number of local sources of 5-HT involving TPH1-expressing cells. As we strive to understand the peripheral actions of 5-HT, it will be important to determine the triggers that release 5-HT from platelets and from the scattered cells that express TPH1, such as marrow cells, osteoblasts, adipocytes and pancreatic β cells. As with many questions in science that we think feel new, but upon closer examination we find were pondered by our predecessors, the puzzle of peripheral 5-HT release mechanisms was appreciated by Vittorio Erspamer. He wrote in 1954: "The conditions which regu late the physio logical liberation of 5-HT from the intact thrombocytes are obscure" (REF. 72 ). And they still are.
Box 1 | Other peripheral actions of serotonin
In addition to the many actions described in this Review, central and peripheral serotonin (5-HT) influences additional biological systems 4, 73 .
Cardiac actions
High 5-HT levels, possibly acting on 5-HT 4 receptors, can cause atrial fibrillation 74 , and 5-HT 4 receptor expression is increased in failing ventricles 75, 76 . Another 5-HT receptor, 5-HT 2B , is expressed on valvular interstitial cells and is activated by fenfluramine (appetite suppressant), causing pathological changes to the valve resulting in poor valve closing 77, 78 .
Pulmonary system
Peripherally, gut-derived 5-HT can pass via the circulation to the lungs, where it has been shown that 5-HT from platelets contributes to the pathogenesis of asthma attacks 70 . Under hypoxic conditions, plasma 5-HT concentrations increase, which results in increased vascular resistance leading to pulmonary artery hypertension 79, 80 .
Pregnancy
Levels of 5-HT are increased in the serum of pregnant women, which probably plays a part in the necessary vascular adaptations. Pre-eclampsia severity has been correlated with increased levels of serum 5-HT 81 . This increase in vascular tone is probably because of increased platelet activation. Furthermore, fetal brain development requires 5-HT, which arises from TPH1-expressing cells in the placenta 82 . After delivery, 5-HT promotes rodent uterine involution 83 and mammillary epithelium expresses TPH1 in response to prolactin 84 .
Genitourinary functions
Increases in central 5-HT delay ejaculation via 5-HT 1B and 5-HT 2C receptors 85 . Chronic administration of selective serotonin reuptake inhibitors can be used 'off label' to treat premature ejaculation 86 . Similarly, micturition is modulated by central 5-HT in which activation of 5-HT 2C receptors delays or prevents urination 87 .
Pain
In inflamed tissue, 5-HT is released and sensitizes nerve fibres, which signal nociception to the central nervous system 88 . Descending modulation of incoming nociception occurs via serotonergic neurons in the brainstem 89 . Ascending serotonergic raphe neurons that project to cortical and limbic regions of the brain modulate the psychological perception of pain 90 .
